Table 1 Comparison of characteristics between patients with and without persistent mutations at each time point.
Variables | Pre-HSCT (n = 132) | Post-HSCT-1m (n = 114) | ||||
|---|---|---|---|---|---|---|
No persistent mutations (n = 75) | Persistent mutations (n = 57) | p-Value | No persistent mutations (n = 91) | Persistent mutations (n = 23) | p-Value | |
Cohort | 0.029 | 0.147 | ||||
Cohort #1 | 42 (56) | 21 (37) | 40 (44) | 14 (61) | ||
Cohort #2 | 33 (44) | 36 (63) | 51 (56) | 9 (39) | ||
Age at HSCT, years | 0.029 | 0.341 | ||||
Median (range) | 45 (19–74) | 54 (19–70) | 48 (19–74) | 55 (21–69) | ||
Age group, n (%) | 0.589 | 0.217 | ||||
<60 years | 62 (83) | 45 (79) | 72 (81) | 16 (70) | ||
≥60 years | 13 (17) | 12 (21) | 17 (19) | 7 (30) | ||
Sex, n (%) | 0.349 | 0.319 | ||||
Male | 43 (57) | 28 (49) | 54 (59) | 11 (48) | ||
Female | 32 (43) | 29 (51) | 37 (41) | 12 (52) | ||
AML type, n (%) | 0.365 | 0.364 | ||||
De novo | 68 (91) | 47 (93) | 77 (85) | 22 (96) | ||
Secondary | 6 (8) | 9 (16) | 12 (13) | 1 (4) | ||
Therapy-related | 1 (1) | 1 (2) | 2 (2) | 0 | ||
WBC count, at diagnosis | 0.520 | 0.806 | ||||
Median (range) | 11.3 (0.5–226.2) | 13.2 (0.6–188.7) | 11.6 (0.5–266.2) | 15.4 (0.6–188.7) | ||
WBC group, at diagnosis, n (%) | 0.090 | 0.464 | ||||
<50 × 109/L | 62 (83) | 40 (70) | 70 (77) | 16 (70) | ||
≥50 × 109/L | 13 (17) | 17 (30) | 21 (23) | 7 (30) | ||
Cytogenetic risk group, n (%)a | 0.147 | 0.408 | ||||
Favorable | 16 (21) | 5 (9) | 14 (15) | 5 (22) | ||
Intermediate | 46 (53) | 41 (72) | 59 (65) | 16 (70) | ||
Adverse | 13 (17) | 11 (19) | 18 (20) | 2 (8) | ||
2017 ELN risk group, n (%) | 0.705 | 0.524 | ||||
Favorable | 28 (37) | 19 (33) | 31 (34) | 10 (43) | ||
Intermediate | 27 (36) | 19 (33) | 35 (38) | 6 (26) | ||
Adverse | 20 (27) | 19 (33) | 25 (28) | 7 (30) | ||
Disease status at HSCT, n (%) | 0.315 | 0.025 | ||||
CR1 | 74 (99) | 54 (95) | 90 (99) | 20 (87) | ||
CR2 | 1 (1) | 3 (5) | 1 (1) | 3 (13) | ||
Donor type, n (%) | 0.189 | 0.943 | ||||
Matched sibling | 12 (16) | 15 (26) | 17 (18) | 4 (17) | ||
Matched unrelated | 34 (45) | 18 (32) | 36 (40) | 10 (44) | ||
Haploidentical | 29 (39) | 24 (42) | 38 (42) | 9 (39) | ||
Relationship, n (%) | 0.109 | 0.732 | ||||
Related | 41 (55) | 39 (68) | 55 (60) | 13 (57) | ||
Unrelated | 34 (45) | 18 (32) | 36 (40) | 10 (43) | ||
Stem cell source, n (%) | 0.633 | - | ||||
Peripheral blood | 72 (96) | 56 (98) | 91 (100) | 23 (100) | ||
Bone marrow | 3 (4) | 1 (2) | 0 | 0 | ||
HLA disparity, n (%) | 0.690 | 0.819 | ||||
Full matched | 46 (61) | 33 (58) | 53 (58) | 14 (61) | ||
Mismatch | 29 (39) | 24 (42) | 38 (42) | 9 (39) | ||
Conditioning intensity, n (%) | 0.281 | 0.119 | ||||
Myeloablative | 36 (48) | 22 (39) | 40 (44) | 6 (26) | ||
Reduced-toxicity | 39 (52) | 35 (61) | 51 (56) | 17 (74) | ||
GVHD prophylaxis, n (%) | 0.146 | 1.000 | ||||
Cyclosporine + MTX | 12 (16) | 15 (26) | 17 (19) | 4 (17) | ||
Tacrolimus + MTX | 63 (84) | 42 (74) | 74 (81) | 19 (83) | ||
ATG, total dose, n (%) | 0.587 | 0.184 | ||||
Not used | 11 (15) | 5 (9) | 10 (11) | 1 (4) | ||
2.5 mg/kg | 29 (39) | 24 (42) | 33 (36) | 13 (57) | ||
5.0 mg/kg | 35 (47) | 28 (49) | 48 (53) | 9 (39) | ||
HCT-CI at HSCT, n (%) | 0.911 | 0.394 | ||||
0–2 | 52 (69) | 39 (68) | 63 (69) | 18 (78) | ||
>2 | 23 (31) | 18 (32) | 28 (31) | 5 (22) | ||
Sex match, n (%) | 0.608 | 0.071 | ||||
Female to male | 13 (17) | 8 (14) | 19 (21) | 1 (4) | ||
Others | 62 (83) | 49 (86) | 72 (79) | 22 (96) | ||
